Innovent Biologics Reports Promising Results in Early-Stage Study of Bispecific Antibody IBI363 in Lung Cancer Patients

Clinical Data Presentation:
Innovent Biologics presented clinical data on IBI363, a first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein, at the 2024 ESMO Virtual Plenary.

Efficacy in NSCLC:
The study showed strong anti-tumor effects in IO-treated squamous NSCLC patients, with an overall response rate (ORR) of 35.1% and a disease control rate (DCR) of 75.5% after a median follow-up of about 5.6 months.

Promising Results in Specific Subgroups:
In a subgroup of patients with squamous cell carcinoma, 13 out of 37 patients experienced a partial response, indicating significant efficacy in this population.

Safety and Tolerability:
IBI363 demonstrated antibody-like pharmacokinetics and low immunogenicity, suggesting good druggability and safety.

Future Potential:
The results suggest that IBI363 could be a breakthrough in treating NSCLC, particularly in patients who have failed previous anti-PD-1/L1 therapies.